Evidence map›Paper›PMID 35093595›Full record

ArticleJournal of gynecology obstetrics and human reproduction2022

Sickle cell disease and COVID-19 in pregnant women.

Kamila Kolanska, Radostina Vasileva, François Lionnet, Aline Santin, Suha Jaudi, Yohann Dabi, Nathalie Chabbert-Buffet, Emile Daraï, Marie Bornes

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecology obstetrics and human reproduction, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kamila KolanskaDepartment of Gynecology Obstetrics and Reproductive Medicine, Tenon Hospital, AP-HP, Sorbonne University, 4 rue de la Chine, Paris 75020, France. Electronic address: kamila.kolanska@aphp.fr.
Radostina VasilevaDepartment of Gynecology Obstetrics and Reproductive Medicine, Tenon Hospital, AP-HP, Sorbonne University, 4 rue de la Chine, Paris 75020, France.
François LionnetDepartment of Internal Medicine, Reference Center of Sickle cell Anemia (AP-HP), University Hospital Center of Tenon, Sorbonne University, rue de la Chine, Paris 75020, France.
Aline SantinDepartment of Internal Medicine, Reference Center of Sickle cell Anemia (AP-HP), University Hospital Center of Tenon, Sorbonne University, rue de la Chine, Paris 75020, France.
Suha JaudiDepartment of Gynecology Obstetrics and Reproductive Medicine, Tenon Hospital, AP-HP, Sorbonne University, 4 rue de la Chine, Paris 75020, France.
Yohann DabiDepartment of Gynecology Obstetrics and Reproductive Medicine, Tenon Hospital, AP-HP, Sorbonne University, 4 rue de la Chine, Paris 75020, France.
Nathalie Chabbert-BuffetDepartment of Gynecology Obstetrics and Reproductive Medicine, Tenon Hospital, AP-HP, Sorbonne University, 4 rue de la Chine, Paris 75020, France.
Emile DaraïDepartment of Gynecology Obstetrics and Reproductive Medicine, Tenon Hospital, AP-HP, Sorbonne University, 4 rue de la Chine, Paris 75020, France.
Marie BornesDepartment of Gynecology Obstetrics and Reproductive Medicine, Tenon Hospital, AP-HP, Sorbonne University, 4 rue de la Chine, Paris 75020, France.
Assistance Publique – Hôpitaux de Paris · FRSorbonne Université · FRHôpital Tenon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe effect of coronavirus disease (COVID-19) on pregnancy outcome in women with sickle cell disease (SCD) is unknown.

objectivesTo analyze the severity of the SARS-CoV-2 infection in pregnant women with SCD and its impact on pregnancy.

methodsThis retrospective cohort study included SCD pregnant women tested positive for COVID-19 between March 2020 - February 2021. The primary endpoint was the severity of the COVID-19 infection. Secondary endpoints were pregnancy complications and fetal outcomes.

resultsDuring the study period among 82 pregnant women with SCD, 8 have presented symptoms suggestive of COVID-19 and were tested positive. A common mild clinical presentation was observed in 6 women (75%), one woman was asymptomatic and one required oxygen. The latter was admitted to the Intensive Care Unit and a cesarean section was performed in the context of an ongoing vaso-occlusive crisis and acute chest syndrome together with incidental preeclampsia. Labor was induced in another patient who developed a vaso-occlusive crisis after COVID-19 remission. Fetal outcomes were good with an average Apgar score of 10 and normal umbilical blood pH at birth. Two newborns were small-for-gestational-age as expected on the ultrasound follow-up before occurrence of COVID-19.

conclusionCOVID-19 infection in our population of pregnant women with SCD had typical presentation and rarely triggered a sickle cell crisis or other complications. Fetal outcomes were good and did not seem to be directly influenced by the SARS-CoV-2 virus. Further studies are required to confirm these observations as compared to the population of women with SCD without COVID-19 infection.

Indexed as

Anemia, Sickle CellCOVID-19Pregnancy Complications, InfectiousCesarean SectionFemaleHumansInfant, NewbornPregnancyPregnancy OutcomePregnant PeopleRetrospective StudiesSARS-CoV-2COVID-19Pregnancy complicationsSickle-cell disease

Identifiers

PMID35093595
PMCPMC8800150
OpenAlexW4210537769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.